UNASSIGNED: Prolonged delayed graft function (DGF) in kidney transplant recipients imparts a risk of poor allograft function; @entity1140 may be detrimental in this setting. We conducted a retrospective single center analysis of the first 20 @entity1 converted to belatacept for prolonged DGF as part of a clinical protocol as a novel treatment strategy to treat prolonged DGF. Prior to conversion @entity1 underwent an allograft biopsy to rule out rejection and confirm @entity810 . The primary outcome was the @entity470 at 12 months post-transplant; secondary outcome was the change in @entity470 30 days post-belatacept conversion. At 1 year post-transplant the mean @entity470 was 54.2 (SD 19.2) mL/min/1.73 m(2) . The mean @entity470 on the day of belatacept conversion was 16 (SD 12.7) mL/min/1.73 m(2) and rose to 43.1 (SD 15.8) mL/min/1.73 m(2) 30 days post-conversion (P <0.0001). The acute rejection rate was 20% with 100% @entity1 survival at 12 months post-transplant. There was one graft loss in the setting of an @entity3 that resulted in withdrawal of immunosuppression and transplant nephrectomy. Belatacept conversion for prolonged DGF is a novel treatment strategy that resulted in an improvement in @entity470 . Additional follow-up is warranted to confirm the long-term benefits of this strategy. This article is protected by copyright. All rights reserved.

Early Post-Transplant Conversion from XXXX to Belatacept for Prolonged Delayed Graft Function Improves Renal Function in Kidney Transplant Recipients.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity470 :: ('1956', 'Gene') :: ['eGFR'] @entity3 :: ('MESH:D009362', 'Disease') :: ['invasive aspergillus infection'] @entity810 :: ('MESH:D058186', 'Disease') :: ['tubular injury'] @entity1140 :: ('MESH:D016559', 'Chemical') :: ['tacrolimus']
@entity1140 :: (MESH:D016559,Chemical) :: ['Tacrolimus']
